CN1527883A - 基于野兔痘的载体疫苗 - Google Patents
基于野兔痘的载体疫苗 Download PDFInfo
- Publication number
- CN1527883A CN1527883A CNA028061020A CN02806102A CN1527883A CN 1527883 A CN1527883 A CN 1527883A CN A028061020 A CNA028061020 A CN A028061020A CN 02806102 A CN02806102 A CN 02806102A CN 1527883 A CN1527883 A CN 1527883A
- Authority
- CN
- China
- Prior art keywords
- virus
- foreign dna
- reorganization
- hare
- vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940126580 vector vaccine Drugs 0.000 title abstract 2
- 241000700605 Viruses Species 0.000 claims abstract description 69
- 239000000427 antigen Substances 0.000 claims abstract description 22
- 108091007433 antigens Proteins 0.000 claims abstract description 22
- 102000036639 antigens Human genes 0.000 claims abstract description 22
- 230000001717 pathogenic effect Effects 0.000 claims abstract description 15
- 208000035473 Communicable disease Diseases 0.000 claims abstract description 12
- 238000011282 treatment Methods 0.000 claims abstract description 8
- 244000052769 pathogen Species 0.000 claims abstract description 6
- 229960005486 vaccine Drugs 0.000 claims description 50
- 230000008521 reorganization Effects 0.000 claims description 46
- 241000700562 Myxoma virus Species 0.000 claims description 33
- 241000714201 Feline calicivirus Species 0.000 claims description 31
- 241000282326 Felis catus Species 0.000 claims description 17
- 241000701931 Canine parvovirus Species 0.000 claims description 14
- 241000283953 Lagomorpha Species 0.000 claims description 14
- 208000015181 infectious disease Diseases 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 11
- 241000282324 Felis Species 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 208000032839 leukemia Diseases 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 230000002458 infectious effect Effects 0.000 claims description 4
- 201000010000 Agranulocytosis Diseases 0.000 claims description 3
- 101710091045 Envelope protein Proteins 0.000 claims description 3
- 101710188315 Protein X Proteins 0.000 claims description 3
- 231100000614 poison Toxicity 0.000 claims description 3
- 108090000565 Capsid Proteins Proteins 0.000 claims description 2
- 239000002574 poison Substances 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 208000010772 Dog disease Diseases 0.000 claims 2
- 102100023321 Ceruloplasmin Human genes 0.000 claims 1
- 102100021696 Syncytin-1 Human genes 0.000 claims 1
- 230000000890 antigenic effect Effects 0.000 abstract description 5
- 108091029865 Exogenous DNA Proteins 0.000 abstract description 4
- 241000251539 Vertebrata <Metazoa> Species 0.000 abstract description 3
- 230000009851 immunogenic response Effects 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 238000002255 vaccination Methods 0.000 abstract description 2
- 241000700563 Leporipoxvirus Species 0.000 abstract 4
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
- 241000894007 species Species 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 description 60
- 108090000623 proteins and genes Proteins 0.000 description 39
- 241000283973 Oryctolagus cuniculus Species 0.000 description 34
- 210000004027 cell Anatomy 0.000 description 32
- 241001465754 Metazoa Species 0.000 description 30
- 238000011081 inoculation Methods 0.000 description 28
- 239000013612 plasmid Substances 0.000 description 27
- 210000002966 serum Anatomy 0.000 description 20
- 238000000034 method Methods 0.000 description 15
- 239000013598 vector Substances 0.000 description 14
- 208000002874 Acne Vulgaris Diseases 0.000 description 12
- 206010000496 acne Diseases 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 230000003612 virological effect Effects 0.000 description 11
- 108091034117 Oligonucleotide Proteins 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 238000010790 dilution Methods 0.000 description 10
- 239000012895 dilution Substances 0.000 description 10
- 230000036039 immunity Effects 0.000 description 10
- 239000012634 fragment Substances 0.000 description 9
- 239000005090 green fluorescent protein Substances 0.000 description 9
- 238000007920 subcutaneous administration Methods 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 210000000234 capsid Anatomy 0.000 description 7
- 210000003292 kidney cell Anatomy 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 208000009091 myxoma Diseases 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 241000700662 Fowlpox virus Species 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 241000287828 Gallus gallus Species 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 238000012408 PCR amplification Methods 0.000 description 5
- 241000700564 Rabbit fibroma virus Species 0.000 description 5
- 241000714203 Rabbit hemorrhagic disease virus Species 0.000 description 5
- 238000010241 blood sampling Methods 0.000 description 5
- 235000013330 chicken meat Nutrition 0.000 description 5
- 238000007918 intramuscular administration Methods 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 101710197665 Capsid protein VP2 Proteins 0.000 description 4
- -1 IP10 Proteins 0.000 description 4
- 241000712079 Measles morbillivirus Species 0.000 description 4
- 206010027336 Menstruation delayed Diseases 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 230000001276 controlling effect Effects 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000008004 immune attack Effects 0.000 description 4
- 238000006386 neutralization reaction Methods 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 229920000136 polysorbate Polymers 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 241000712083 Canine morbillivirus Species 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 101900316143 Feline calicivirus Capsid protein Proteins 0.000 description 3
- 101150066002 GFP gene Proteins 0.000 description 3
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 3
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 3
- 102100034349 Integrase Human genes 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 235000014676 Phragmites communis Nutrition 0.000 description 3
- 241000282898 Sus scrofa Species 0.000 description 3
- 108010008038 Synthetic Vaccines Proteins 0.000 description 3
- 241000700618 Vaccinia virus Species 0.000 description 3
- 108020005202 Viral DNA Proteins 0.000 description 3
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000013016 damping Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000008676 import Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 210000001331 nose Anatomy 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 229940124551 recombinant vaccine Drugs 0.000 description 3
- 238000010257 thawing Methods 0.000 description 3
- 239000003104 tissue culture media Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 101710083734 CTP synthase Proteins 0.000 description 2
- 102100039866 CTP synthase 1 Human genes 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 241000713800 Feline immunodeficiency virus Species 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 2
- 101000947178 Homo sapiens Platelet basic protein Proteins 0.000 description 2
- 102000003810 Interleukin-18 Human genes 0.000 description 2
- 108090000171 Interleukin-18 Proteins 0.000 description 2
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 2
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 241000009328 Perro Species 0.000 description 2
- 230000010748 Photoabsorption Effects 0.000 description 2
- 102100036154 Platelet basic protein Human genes 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 101800001271 Surface protein Proteins 0.000 description 2
- 241000607479 Yersinia pestis Species 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 108700004025 env Genes Proteins 0.000 description 2
- 101150030339 env gene Proteins 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 102000057593 human F8 Human genes 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000003360 nephrocyte Anatomy 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229940047431 recombinate Drugs 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 210000003501 vero cell Anatomy 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MEIRRNXMZYDVDW-MQQKCMAXSA-N (2E,4E)-2,4-hexadien-1-ol Chemical compound C\C=C\C=C\CO MEIRRNXMZYDVDW-MQQKCMAXSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 108020005065 3' Flanking Region Proteins 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 102000016614 Autophagy-Related Protein 5 Human genes 0.000 description 1
- 108010092776 Autophagy-Related Protein 5 Proteins 0.000 description 1
- 241000283725 Bos Species 0.000 description 1
- 102100023702 C-C motif chemokine 13 Human genes 0.000 description 1
- 101710112613 C-C motif chemokine 13 Proteins 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 102100032366 C-C motif chemokine 7 Human genes 0.000 description 1
- 101710155834 C-C motif chemokine 7 Proteins 0.000 description 1
- 102100034871 C-C motif chemokine 8 Human genes 0.000 description 1
- 101710155833 C-C motif chemokine 8 Proteins 0.000 description 1
- 102100039398 C-X-C motif chemokine 2 Human genes 0.000 description 1
- 102000001902 CC Chemokines Human genes 0.000 description 1
- 108010040471 CC Chemokines Proteins 0.000 description 1
- 101900009576 Canine coronavirus Spike glycoprotein Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 101800001383 Capsid protein VP60 Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 102000016950 Chemokine CXCL1 Human genes 0.000 description 1
- 108010014419 Chemokine CXCL1 Proteins 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102400000498 Connective tissue-activating peptide III Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 241000711475 Feline infectious peritonitis virus Species 0.000 description 1
- 241000701915 Feline panleukopenia virus Species 0.000 description 1
- 208000000666 Fowlpox Diseases 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101000889128 Homo sapiens C-X-C motif chemokine 2 Proteins 0.000 description 1
- 101000973997 Homo sapiens Nucleosome assembly protein 1-like 4 Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102100030304 Platelet factor 4 Human genes 0.000 description 1
- 108090000778 Platelet factor 4 Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 101710181917 Serine proteinase inhibitor 1 Proteins 0.000 description 1
- 101710181913 Serine proteinase inhibitor 2 Proteins 0.000 description 1
- 241000287219 Serinus canaria Species 0.000 description 1
- 208000001203 Smallpox Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 101710198474 Spike protein Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 101150003725 TK gene Proteins 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000870995 Variola Species 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 229910052728 basic metal Inorganic materials 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 210000003837 chick embryo Anatomy 0.000 description 1
- 229940001442 combination vaccine Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 108010035886 connective tissue-activating peptide Proteins 0.000 description 1
- 229940028617 conventional vaccine Drugs 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 201000003740 cowpox Diseases 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000002223 garnet Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- AEUKDPKXTPNBNY-XEYRWQBLSA-N mcp 2 Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)C1=CC=CC=C1 AEUKDPKXTPNBNY-XEYRWQBLSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 229940031348 multivalent vaccine Drugs 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 239000005723 virus inoculator Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/23—Parvoviridae, e.g. feline panleukopenia virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/16011—Caliciviridae
- C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
质粒 | 重组病毒 | 株号 |
pVL/GFP | Myxo/GFP | 未确定 |
pVL/VP60 | Myxo/RHD | 未确定 |
pVEL/FeL Venv | Myxo/FeL Venv | MS0011 |
pVEL/FCV | Myxo/FCV | MS0013 |
pVL/FCV | Myxo/FCV | MS0014 |
pVEL/FPL | Myxo/FPL | MS0015 |
pVEL/CPV | Myxo/CPV | MS0016 |
接种途径 | 动物数量 | 血细胞凝集反应抑制滴度 | ||
第0天 | 第14天 | 第28天 | ||
肌内 | 166 | 0 | 80 | 40 |
168 | 0 | 40 | 20 | |
170 | 0 | 640-1280 | 640-1280 | |
172 | 0 | 40 | 40 | |
174 | 0 | 320 | 320 | |
176 | 0 | 40 | 160 | |
178 | 0 | 320 | 640 | |
180 | 0 | 40 | 40 | |
皮下 | 182 | 0 | 320 | 320 |
184 | 0 | 40 | 20 | |
186 | 0 | 10 | 10 | |
189 | 0 | 320-640 | 320 | |
191 | 0 | 40 | 40 | |
193 | 0 | 20 | 20 | |
195 | 0 | 640 | 640 | |
197 | 0 | 320 | 320 | |
对照 | 290 | 0 | 0 | 0 |
292 | 0 | 0 | 0 | |
294 | 0 | 0 | 0 | |
296 | 0 | 0 | 0 | |
298 | 0 | 0 | 0 |
时间点 | 动物组 | 操作 |
第-1天 | 1和2 | 鼻孔擦拭O/P,采血 |
第0天 | 1 | 疫苗接种 |
第21天 | 1 | 采血和第二次疫苗接种 |
第49天 | 1和2 | 采血和免疫攻击 |
第50-62天 | 1和2 | 临床监察,鼻孔擦拭O/P |
第63天 | 1和2 | 临床监察,采血,鼻孔擦拭O/P, |
血清 | 前血 | 第一次疫苗接种后 | 第二次疫苗接种后 | 免疫攻击后 | 临床分值* | |
猫序号 | 组 | |||||
358-054 | 疫苗接种组(组1) | <1∶4 | 1∶102 | 1∶2580 | 10321 | 1 |
376-561 | <1∶4 | 1∶50 | 1∶1024 | >16384 | 13 | |
383-882 | <1∶4 | 1∶215 | 1∶3444 | 13777 | 0 | |
073-609 | <1∶4 | 1∶161 | 1∶1569 | 16384 | 4 | |
295-099 | 对照(组2) | <1∶4 | <1∶4 | <1∶5 | 1337 | 49 |
375-369 | <1∶4 | <1∶4 | <1∶4 | 4096 | 18 | |
078-001 | <1∶4 | <1∶4 | <1∶4 | 2435 | 47 | |
268-054 | <1∶4 | <1∶4 | <1∶4 | 697 | 22 |
日期 | 活性 |
T=-7天 | 采集前血清样本 |
T=0天 | 按照1ml PBS含有1×108FFU重组粘液瘤病毒/每种注射途径/每只动物的剂量进行皮下或者肌内注射 |
T=28天 p.i. | 采集血液样本(10ml) |
T=28天 p.i. | 按照1ml PBS含有1×108FFU重组粘液瘤病毒/每种注射途径/每只动物的剂量进行皮下或者肌内注射 |
T=42天 p.i. | 采集血液样本 |
T=42天 p.i. | 结束试验 |
动物 | 前血 | 一次疫苗接种后 | 二次疫苗接种后 |
牛2403 | <=1∶4 | 1∶54 | >=1∶724 |
牛1948 | <=1∶4 | 1∶64 | >=1∶1024 |
牛1603 | <=1∶4 | 1∶13 | 1∶256 |
牛1190 | <=1∶4 | 1∶54 | >=1∶861 |
猪122 | <=1∶4 | <=1∶4 | 1∶304 |
猪119 | <=1∶4 | <=1∶4 | 1∶304 |
猪118 | <=1∶4 | 1∶10 | 1∶256 |
猪117 | <=1∶4 | <=1∶4 | >=1∶861 |
疫苗 | 指示的稀释度的光吸收10 20 40 80 160 320 640 1280 | |||||||
Myxo-Vp2 | >2.0 | >2.0 | 1.8 | 1.56 | 1.198 | 0.685 | 0.45 | 0.297 |
传统疫苗 | 0.73 | 0.46 | 0.29 | 0.30 | 0.28 | 0.30 | 0.26 | 0.29 |
无 | 0.31 | 0.28 | 0.30 | 0.26 | 0.28 | 0.25 | 0.27 | 0.26 |
Claims (11)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01200869.4 | 2001-03-08 | ||
EP01200869 | 2001-03-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1527883A true CN1527883A (zh) | 2004-09-08 |
CN1258596C CN1258596C (zh) | 2006-06-07 |
Family
ID=8179978
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN02806102.0A Expired - Fee Related CN1258596C (zh) | 2001-03-08 | 2002-03-07 | 基于野兔痘的载体疫苗 |
Country Status (17)
Country | Link |
---|---|
US (1) | US6942864B2 (zh) |
EP (1) | EP1370668B1 (zh) |
JP (1) | JP4037273B2 (zh) |
CN (1) | CN1258596C (zh) |
AT (1) | ATE318321T1 (zh) |
AU (1) | AU2002304856B2 (zh) |
BR (1) | BR0207761A (zh) |
CA (1) | CA2439872C (zh) |
DE (1) | DE60209345T2 (zh) |
DK (1) | DK1370668T3 (zh) |
ES (1) | ES2258628T3 (zh) |
MX (1) | MXPA03007862A (zh) |
NO (1) | NO331305B1 (zh) |
NZ (1) | NZ527940A (zh) |
PT (1) | PT1370668E (zh) |
WO (1) | WO2002072852A2 (zh) |
ZA (1) | ZA200306607B (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ572893A (en) * | 2006-06-01 | 2011-06-30 | Robarts Res Inst | Myxoma virus mutants for cancer treatment |
KR100831536B1 (ko) * | 2007-01-19 | 2008-05-22 | 리엔 창 일렉트로닉 엔터프라이즈 컴퍼니 리미티드 | 풀 브릿지 드라이버 |
KR100831537B1 (ko) * | 2007-01-19 | 2008-05-22 | 리엔 창 일렉트로닉 엔터프라이즈 컴퍼니 리미티드 | 하프 브릿지 드라이버 |
FR2925067B1 (fr) * | 2007-12-18 | 2010-01-15 | Agronomique Inst Nat Rech | Vecteurs vaccinaux derives de leporipoxvirus |
WO2021202971A1 (en) * | 2020-04-02 | 2021-10-07 | Arizona Board Of Regents On Behalf Of Arizona State University | Covid-19 vaccine based on the myxoma virus platform |
CN111904981A (zh) * | 2020-09-07 | 2020-11-10 | 威世药业(如皋)有限公司 | 一种痘苗病毒致炎兔皮生产方法 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5833975A (en) * | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
US5505941A (en) * | 1981-12-24 | 1996-04-09 | Health Research, Inc. | Recombinant avipox virus and method to induce an immune response |
US5174993A (en) * | 1981-12-24 | 1992-12-29 | Health Research Inc. | Recombinant avipox virus and immunological use thereof |
DE10399031I1 (de) * | 1987-08-28 | 2004-01-29 | Health Research Inc | Rekombinante Viren. |
AU2347692A (en) | 1991-07-09 | 1993-02-11 | Cornell Research Foundation Inc. | Recombinant viral vaccine |
TW377373B (en) | 1993-09-22 | 1999-12-21 | Wyeth Corp | Recombinant raccoon pox viruses and their use as an effective vaccine against feline infectious peritonitis virus disease |
US6001349A (en) * | 1995-02-22 | 1999-12-14 | Therion Biologics Corporation | Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof |
FR2736358B1 (fr) | 1995-07-05 | 1997-09-26 | Agronomique Inst Nat Rech | Virus myxomateux recombinant |
AU4266597A (en) * | 1996-09-11 | 1998-04-14 | General Hospital Corporation, The | Use of a non-mammalian dna virus to express an exogenous gene in a mammalian cell |
US6127172A (en) * | 1998-05-29 | 2000-10-03 | University Of Florida | Materials and methods for delivery and expression of heterologous DNA in vertebrate cells |
ES2153284B1 (es) * | 1998-06-10 | 2001-09-01 | Fundacion Para El Estudio Y De | Nuevo virus recombinante de mixoma atenuado y su uso en la preparacion de vacunas mixtas contra la mixomatosis y la enfermedad hemorragica de los conejos. |
US6294176B1 (en) * | 1998-07-10 | 2001-09-25 | Schering-Plough Veterinary Corp. | Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species |
-
2002
- 2002-03-07 CN CN02806102.0A patent/CN1258596C/zh not_active Expired - Fee Related
- 2002-03-07 EP EP02732485A patent/EP1370668B1/en not_active Expired - Lifetime
- 2002-03-07 NZ NZ527940A patent/NZ527940A/en not_active IP Right Cessation
- 2002-03-07 BR BR0207761-2A patent/BR0207761A/pt not_active IP Right Cessation
- 2002-03-07 AU AU2002304856A patent/AU2002304856B2/en not_active Ceased
- 2002-03-07 DE DE60209345T patent/DE60209345T2/de not_active Expired - Lifetime
- 2002-03-07 ES ES02732485T patent/ES2258628T3/es not_active Expired - Lifetime
- 2002-03-07 CA CA002439872A patent/CA2439872C/en not_active Expired - Fee Related
- 2002-03-07 JP JP2002571903A patent/JP4037273B2/ja not_active Expired - Fee Related
- 2002-03-07 PT PT02732485T patent/PT1370668E/pt unknown
- 2002-03-07 AT AT02732485T patent/ATE318321T1/de not_active IP Right Cessation
- 2002-03-07 US US10/471,300 patent/US6942864B2/en not_active Expired - Fee Related
- 2002-03-07 MX MXPA03007862A patent/MXPA03007862A/es active IP Right Grant
- 2002-03-07 WO PCT/EP2002/002858 patent/WO2002072852A2/en active IP Right Grant
- 2002-03-07 DK DK02732485T patent/DK1370668T3/da active
-
2003
- 2003-08-25 ZA ZA2003/06607A patent/ZA200306607B/en unknown
- 2003-09-04 NO NO20033912A patent/NO331305B1/no not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CA2439872C (en) | 2009-12-15 |
CN1258596C (zh) | 2006-06-07 |
DE60209345T2 (de) | 2006-08-03 |
CA2439872A1 (en) | 2002-09-19 |
EP1370668A2 (en) | 2003-12-17 |
BR0207761A (pt) | 2006-01-31 |
MXPA03007862A (es) | 2004-05-24 |
NO20033912D0 (no) | 2003-09-04 |
EP1370668B1 (en) | 2006-02-22 |
US6942864B2 (en) | 2005-09-13 |
WO2002072852A3 (en) | 2002-12-27 |
US20040137599A1 (en) | 2004-07-15 |
AU2002304856B2 (en) | 2006-08-24 |
JP2004528833A (ja) | 2004-09-24 |
NO20033912L (no) | 2003-10-22 |
JP4037273B2 (ja) | 2008-01-23 |
NZ527940A (en) | 2005-01-28 |
ES2258628T3 (es) | 2006-09-01 |
WO2002072852A2 (en) | 2002-09-19 |
DE60209345D1 (de) | 2006-04-27 |
DK1370668T3 (da) | 2006-06-06 |
NO331305B1 (no) | 2011-11-21 |
ZA200306607B (en) | 2005-02-23 |
ATE318321T1 (de) | 2006-03-15 |
PT1370668E (pt) | 2006-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1056878C (zh) | 重组火鸡疱疹病毒及其衍生的活载体疫苗 | |
JP5106398B2 (ja) | Pcv−2ワクチン | |
JP6096176B2 (ja) | ブタウイルス感染の予防のための混合ワクチン | |
CN1912112A (zh) | 重组的感染性不分节段的负链rna病毒 | |
CN1940063A (zh) | 一种伪狂犬病gEˉ/gIˉ基因缺失毒株、含有该毒株的灭活疫苗及应用 | |
CN111876391A (zh) | 猫泛白细胞减少症病毒fpv bj05株及其应用 | |
CN1800374A (zh) | 一种重组伪狂犬病-猪繁殖与呼吸综合征基因工程毒株及应用 | |
JP7387623B2 (ja) | 標的タンパク質を安定して発現できる組換えウイルス | |
CN1258596C (zh) | 基于野兔痘的载体疫苗 | |
CN1295339C (zh) | 减毒痘苗病毒天坛株载体及制备方法和应用 | |
JP2020537651A (ja) | 昆虫細胞でのPCV2b ORF2タンパク質の組換え発現 | |
CN1654666A (zh) | 减毒痘苗病毒天坛株载体及制备方法和应用 | |
CN114921422B (zh) | 一种犬源猫细小病毒分离株及其应用 | |
JPS637754B2 (zh) | ||
CN1225553C (zh) | 表达猪细小病毒vp2基因的重组伪狂犬病毒及疫苗与制备方法 | |
Li et al. | Immunogenicity assessment of rift valley fever virus virus-like particles in BALB/c mice | |
CN115161291A (zh) | 一株猫细小病毒毒株及其应用 | |
AU2002304856A1 (en) | Leporipox-based vector vaccines | |
CN1283788C (zh) | 表达猪繁殖与呼吸综合征病毒的重组伪狂犬病毒及应用 | |
Frossard | Retroviridae | |
CN117568288B (zh) | 一种高效拯救禽冠状病毒的方法及其应用 | |
US11033616B2 (en) | Recombinant viral vector systems expressing exogenous feline paramyxovirus genes and vaccines made therefrom | |
CN114107227B (zh) | 一种同时表达经典株和变异株传染性法氏囊病毒vp2蛋白的重组火鸡疱疹病毒活载体疫苗 | |
JP4856939B2 (ja) | 感染症予防ワクチン | |
CN1264975C (zh) | 轮状病毒基因重配株 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: INTERVET INTERNATIONAL CO., LTD. Free format text: FORMER OWNER: AKZO NOVEL N.V. CORP. Effective date: 20061208 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20061208 Address after: Holland Haier box Patentee after: Intervet International Co., Ltd. Address before: Holland Arnhem Patentee before: Akzo Nobel N. V. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060607 Termination date: 20170307 |